Trial Profile
Exploratory Research on Prognosis Factors and Risk-factors of Adverse Drug Reactions in the Adjuvant Chemotherapy with S-1 for Patients with Curatively Resected Gastric Cancer [SUBSTUDY OF 700231179]
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2013 New trial record